NCT03059355终止1 期
A Phase I/II, Randomized, Placebo-controlled Comparative Study to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Bone Marrow (BM) Derived MSCs to Evaluate Cytokine Suppression in Patients With Chronic Inflammation Due to Metabolic Syndrome.
Joshua M Hare2 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2018年4月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 14
- 试验地点
- 2
- 主要终点
- Number of Treatment-Emergent Serious Adverse Events (TE-SAEs)
研究概览
简要总结
This study is to compare the safety and efficacy of UCMSCs and BMMSCs administered intravenously in patients to evaluate cytokine suppression in patients with chronic inflammation. Cells administered via intravenous infusion (IV) and will be tested in 37 patients in two phases (Pilot and Randomized).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Pilot phase is open-label. Randomized phase is blinded.
入排标准
- 年龄范围
- 21 Years 至 95 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide written informed consent
- •Subjects age > 21 and < 95 years at the time of signing the Informed Consent Form.
- •Each subject must have endothelial dysfunction.
- •Endothelial dysfunction Criteria:
- •Impaired flow-mediated vasodilation (FMD <7%)
- •At the time of enrollment, each subject must meet at least 3 out of the 5 criteria under the harmonized definition of the metabolic syndrome, consisting of the following:
- •Waist circumference - US defined: ≥ 102 cm (males) or ≥ 88 cm (females)
- •Elevated triglycerides - ≥ 150 mg/dL (1.7 mM)
- •Reduced HDL-C - Males: <40 mg/dL (1.0 mM) Females: <50 mg/dL (1.3 mM)
- •Elevated blood pressure - Systolic ≥ 130 mm Hg and/or Diastolic ≥ 85 mm Hg
- •Elevated fasting glucose - ≥ 100 mg/dL
排除标准
- •Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female subjects must undergo a blood or urine pregnancy test at screening and within 36 hours prior to infusion.
- •Inability to perform any of the assessments required for endpoint analysis.
- •Active listing (or expected future listing) for transplant of any organ.
- •Clinically important abnormal screening laboratory values, as determined by the P.I.
- •Serious comorbid illness or any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study.
- •Have known allergies to penicillin or streptomycin.
- •Hypersensitivity to dimethyl sulfoxide (DMSO).
- •Be a solid organ transplant recipient. This does not include prior cell-based therapy (>12 months prior enrollment) bone, skin, ligament, tendon or corneal grafting. Have a history of organ or cell transplant rejection.
- •Have a clinical history of malignancy within 3 years (i.e., subjects with prior malignancy must be disease free for 3 years), except curatively- treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma, if recurrence occurs.
- •Have a non-pulmonary condition that limits lifespan to < 1 year.
- •History of drug abuse (illegal "street" drugs except marijuana, or prescription medications not being used appropriately for a pre-existing medical condition) or alcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months.
- •Be serum positive for HIV, hepatitis B surface antigen or Viremic hepatitis C, and/or Syphilis.
- •Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.
- •Patients with Ejection Fraction <45% (heart failure patients).
- •Glomerular Filtration Rate < or equal to 35 (chronic kidney disease stage 3 or higher).
- •Liver disease (elevated Liver Function Tests greater than 3x normal limit).
- •Advanced pulmonary disease (requiring home oxygen and/or less than 1 expected life span).
- •Proliferative diabetic retinopathy
- •Hemoglobin A1C greater than 7.
结局指标
主要结局
Number of Treatment-Emergent Serious Adverse Events (TE-SAEs)
时间窗: one month post infusion
Number of treatment-emergent serious adverse events (SAE) (at one-month post infusion), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities, determined per the Investigator's judgment.
次要结局
- Endothelial Progenitor Cell-Colony Forming Units (EPC-CFUs)(at Baseline, and at 3 months)
- hsCRP Levels(at Baseline, at Week 2, at Month 1, at Month 3, and at Month 6)
- Stem Cell Factor (SCF) Levels(at Baseline, at Week 2, at Month 1, at Month 3, and at Month 6)
- Cytokine Levels(at Baseline, at Week 2, at Month 1, at Month 3, and at Month 6)
- Flow Mediated Diameter Percentage (FMD%)(at Baseline and at Month 3)
研究者
Joshua M Hare
Director of ISCI, Louis Lemberg Professor of Medicine
University of Miami
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Double-blind, Randomized, Controlled Clinical Trial to Assess Efficacy of MSC in Patients With COVID-19 ARDSCOVID-19 PneumoniaAcute Respiratory Distress SyndromeNCT04615429Cristina Avendaño Solá20
Unknown
2 期
The Role of MSC in the Treatment of Fistulas in Patients With Perianal Crohn's DiseaseCrohn's DiseaseFistulaNCT03056664Sixth Affiliated Hospital, Sun Yat-sen University3
已完成
1 期
Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy VolunteersHealthy VolunteersNCT03146416Regeneron Pharmaceuticals96
已完成
2 期
Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid ArthritisRheumatoid ArthritisNCT00292422Biogen50
Unknown
3 期
Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque PsoriasisModerate-to-Severe Plaque PsoriasisNCT04839016Jiangsu HengRui Medicine Co., Ltd.660